Aptus Pharma Q1 FY26 IPO Drama – ₹24.64 Cr Revenue, 288% PAT Growth, P/E Now 15.49x!
1. At a Glance
Welcome to the latest pharma IPO circus – Aptus Pharma. A company that sells medicines but gives investors headaches with its IPO pricing. With revenue up 38% and profit jumping 288% in FY25, Aptus suddenly looks like the Ranveer Singh of the SME market – over-energetic, overdressed, and maybe overvalued. At a P/E of 15.49x post issue, this tiny ₹48 crore market-cap firm is demanding attention like a toddler in a mall. But are they really curing diseases, or just distributing someone else’s pills with extra GST?
2. Introduction
Pharma companies in India are like chai tapris – you’ll find them at every corner, with everyone claiming their formula is “unique.” Aptus Pharma, incorporated in 2010, doesn’t make medicines in its own shiny labs. Instead, it outsources manufacturing to third-party facilities and then does the real business of marketing and distribution. Think of it as Swiggy for pills – only instead of biryani and momos, they deliver antibiotics and PPIs.
Now, why is this smallcap company with a warehouse the size of a Gujarati shaadi pandal suddenly knocking on Dalal Street’s door? The answer: ₹13.02 crores. Yes, the IPO proceeds are mainly for office furniture, racks, and working capital. Imagine asking investors for money just to buy almirahs. Respect.
But here’s the twist – despite not owning factories, Aptus posted 3.1 crore PAT in FY25 compared to 0.8 crore in FY24. This jump is bigger than Shahid Afridi’s batting strike rate in his prime. Skeptics are wondering if this is sustainable growth or just a sugar rush before IPO.
So, are we looking at a future Sun Pharma in toddler form, or another SME IPO where the only real innovation is creative accounting? Let’s investigate.
3. Business Model – WTF Do They Even Do?
Aptus Pharma’s business is less about test tubes and more about distribution routes. Here’s the breakdown:
Aptus CD Care → chronic therapies (diabetes, heart, psych).
Aptus Wellcare → wellness, nutraceuticals (read: vitamins and sachets).
Aptus Global → exports (aka sending the same drugs abroad but with fancier packaging).
They cover 11 therapeutic areas with 194 formulations, from syrups to injectables. Their sales army of 54 field reps is backed by 125 distributors, which means they have more people pushing drugs than the number of active investors applying for SME IPOs these days.
But the roast? Aptus doesn’t own a single big factory. Their “strategic alliances” with manufacturers in Gujarat, Uttarakhand, and Himachal Pradesh are basically outsourcing deals. In short – others sweat in the lab, Aptus gets the credit.
Question for you: If you’re buying a tablet, do you really care who marketed it, or who actually made it?
4. Financials Overview
Source table
Metric
Latest Qtr (Q1 FY26*)
YoY Qtr (Q1 FY25*)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
6.50
4.70
6.10
38.3%
6.6%
EBITDA
1.25
0.40
1.20
212.5%
4.2%
PAT
0.80
0.20
0.75
300.0%
6.7%
EPS (₹)
1.00
0.25
0.95
300.0%
5.3%
*Estimated run-rate from FY25 data (RHP didn’t disclose Q1 separately, so we’ve annualised and interpolated).
Witty Commentary: This company’s EPS grew faster than Bollywood actors’ hair transplants. But remember, EPS here is like instant noodles – quick to rise, equally quick to collapse if the seasoning (outsourcing deals) changes.
